Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Medical Microbiology and Immunology
Published in: Medical Microbiology and Immunology 2/2008

01-06-2008 | Review

New tools to study the role of B cells in cytomegalovirus infections

Authors: Ari Waisman, Andrew L. Croxford, Filiz Demircik

Published in: Medical Microbiology and Immunology | Issue 2/2008

Login to get access

Abstract

B cells were previously shown to mediate partial protection against CMV infection, as in the absence of B cells, latently infected mice were more susceptible to virus reactivation. It remains unclear if this effect stems from the loss of B cells as antibody producers or as antigen presenting cells. To address this fundamental question, we propose to make use of new mouse models that allow conditional ablation of B cells or that allow for the generation of mice with B cells that are not able to produce antibodies.
Literature
1.
Reddehase MJ (2002) Antigens and immunoevasins: opponents in cytomegalovirus immune surveillance. Nat Rev Immunol 2:831–844CrossRefPubMed
2.
Hsieh SM, Pan SC, Hung CC, Tsai HC, Chen MY, Chang SC (2001) Association between cytomegalovirus-specific reactivity of T cell subsets and development of cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome [see comment]. J Infect Dis 184:1386–1391CrossRefPubMed
3.
Lilleri D, Piccinini G, Baldanti F, Seminari E, Galloni D, Gerna G (2003) Multiple relapses of human cytomegalovirus retinitis during HAART in an AIDS patient with reconstitution of CD4+ T cell count in the absence of HCMV-specific CD4+ T cell response. J Clin Virol 26:95–100CrossRefPubMed
4.
Rubin RH (1990) Impact of cytomegalovirus infection on organ transplant recipients. Rev Infect Dis 12 Suppl 12(Suppl 7):S754–S766CrossRef
5.
Crawford SW, Longton G, Storb R (1993) Acute graft-versus-host disease and the risks for idiopathic pneumonia after marrow transplantation for severe aplastic anemia. Bone Marrow Transplant 12:225–231PubMed
6.
Mach M (2006) Antibody-mediated neutralization of infectivity. In: Reddehase MJ (ed) Cytomegaloviruses: molecular biology and immunology. Caister Academic Press, Norfolk (UK), pp 265–283
7.
Shanley JD, Jordan MC, Stevens JG (1981) Modification by adoptive humoral immunity of murine cytomegalovirus infection. J Infect Dis 143:231–237CrossRefPubMed
8.
Reddehase MJ, Balthesen M, Rapp M, Jonjic S, Pavic I, Koszinowski UH (1994) The conditions of primary infection define the load of latent viral genome in organs and the risk of recurrent cytomegalovirus disease. J Exp Med 179:185–193CrossRefPubMed
9.
Farrell HE, Shellam GR (1991) Protection against murine cytomegalovirus infection by passive transfer of neutralizing and non-neutralizing monoclonal antibodies. J Gen Virol 72(Pt 1):149–156CrossRefPubMed
10.
Jonjic S, Pavic I, Polic B, Crnkovic I, Lucin P, Koszinowski UH (1994) Antibodies are not essential for the resolution of primary cytomegalovirus infection but limit dissemination of recurrent virus. J Exp Med 179:1713–1717CrossRefPubMed
11.
Polic B, Hengel H, Krmpotic A, Trgovcich J, Pavic I, Luccaronin P, Jonjic S, Koszinowski UH (1998) Hierarchical and redundant lymphocyte subset control precludes cytomegalovirus replication during latent infection. J Exp Med 188:1047–1054CrossRefPubMedPubMedCentral
12.
Klenovsek K, Weisel F, Schneider A, Appelt U, Jonjic S, Messerle M, Bradel-Tretheway B, Winkler TH, Mach M (2007) Protection from CMV infection in immunodeficient hosts by adoptive transfer of memory B cells. Blood 110:3472–3479CrossRefPubMed
13.
Cerny A, Sutter S, Bazin H, Hengartner H, Zinkernagel RM (1988) Clearance of lymphocytic choriomeningitis virus in antibody- and B-cell-deprived mice. J Virol 62:1803–1807CrossRefPubMedPubMedCentral
14.
Fillatreau S, Radbruch A (2006) IRF4—a factor for class switching and antibody secretion. Nat Immunol 7:704–706CrossRefPubMed
15.
Ahuja A, Shupe J, Dunn R, Kashgarian M, Kehry MR, Shlomchik MJ (2007) Depletion of B cells in murine lupus: efficacy and resistance. J Immunol 179:3351–3361CrossRefPubMed
16.
Kessel A, Rosner I, Toubi E (2008) Rituximab: beyond simple B cell depletion. Clin Rev Allergy Immunol 34:74–79CrossRefPubMed
17.
18.
Kitamura D, Roes J, Kuhn R, Rajewsky K (1991) A B cell-deficient mouse by targeted disruption of the membrane exon of the immunoglobulin mu chain gene. Nature 350:423–426CrossRefPubMed
19.
Mozdzanowska K, Furchner M, Maiese K, Gerhard W (1997) CD4+ T cells are ineffective in clearing a pulmonary infection with influenza type A virus in the absence of B cells. Virology 239:217–225CrossRefPubMed
20.
Buendia AJ, Martinez CM, Ortega N, Del Rio L, Caro MR, Gallego MC, Sanchez J, Navarro JA, Cuello F, Salinas J (2004) Natural killer (NK) cells play a critical role in the early innate immune response to Chlamydophila abortus infection in mice. J Comp Pathol 130:48–57CrossRefPubMed
21.
Hasan M, Polic B, Bralic M, Jonjic S, Rajewsky K (2002) Incomplete block of B cell development and immunoglobulin production in mice carrying the muMT mutation on the BALB/c background. Eur J Immunol 32:3463–3471CrossRefPubMed
22.
Macpherson AJ, Lamarre A, McCoy K, Harriman GR, Odermatt B, Dougan G, Hengartner H, Zinkernagel RM (2001) IgA production without mu or delta chain expression in developing B cells. Nat Immunol 2:625–631CrossRefPubMed
23.
Gu H, Zou YR, Rajewsky K (1993) Independent control of immunoglobulin switch recombination at individual switch regions evidenced through Cre-loxP-mediated gene targeting. Cell 73:1155–1164CrossRefPubMed
24.
Bradley LM, Harbertson J, Biederman E, Zhang Y, Bradley SM, Linton PJ (2002) Availability of antigen-presenting cells can determine the extent of CD4 effector expansion and priming for secretion of Th2 cytokines in vivo. Eur J Immunol 32:2338–2346CrossRefPubMed
25.
Jung S, Unutmaz D, Wong P, Sano G, De los Santos K, Sparwasser T, Wu S, Vuthoori S, Ko K, Zavala F et al (2002) In vivo depletion of CD11c(+) dendritic cells abrogates priming of CD8(+) T cells by exogenous cell-associated antigens. Immunity 17:211–220CrossRefPubMedPubMedCentral
26.
Buch T, Heppner FL, Tertilt C, Heinen TJ, Kremer M, Wunderlich FT, Jung S, Waisman A (2005) A Cre-inducible diphtheria toxin receptor mediates cell lineage ablation after toxin administration. Nat Methods 2:419–426CrossRefPubMed
27.
Waisman A, Kraus M, Seagal J, Ghosh S, Melamed D, Song J, Sasaki Y, Classen S, Lutz C, Brombacher F et al (2007) IgG1 B cell receptor signaling is inhibited by CD22 and promotes the development of B cells whose survival is less dependent on Ig{alpha}/{beta}. J Exp Med 204:747–758CrossRefPubMedPubMedCentral
Metadata
Title
New tools to study the role of B cells in cytomegalovirus infections
Authors
Ari Waisman
Andrew L. Croxford
Filiz Demircik
Publication date
01-06-2008
Publisher
Springer Berlin Heidelberg
Published in
Medical Microbiology and Immunology / Issue 2/2008
Print ISSN: 0300-8584
Electronic ISSN: 1432-1831
DOI
https://doi.org/10.1007/s00430-008-0088-z

Other articles of this Issue 2/2008

Medical Microbiology and Immunology 2/2008 Go to the issue

Review

Human cytomegalovirus infection and antiviral immunity in septic patients without canonical immunosuppression

Review

Interplay between human cytomegalovirus and dendritic cells in T cell activation

Original Investigation

Refinement of strategies for the development of a human cytomegalovirus dense body vaccine

Original Investigation

Hematopoietic stem cell transplantation with latently infected donors does not transmit virus to immunocompromised recipients in the murine model of cytomegalovirus infection

Review

Recombinant viruses as tools to study human cytomegalovirus immune modulation

Review

Activation of hepatic natural killer cells and control of liver-adapted lymphoma in the murine model of cytomegalovirus infection
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits